The Experts below are selected from a list of 70395 Experts worldwide ranked by ideXlab platform

Yadollah Omidi - One of the best experts on this subject based on the ideXlab platform.

  • improved soluble scfv elisa screening approach for antibody discovery using phage Display Technology
    SLAS DISCOVERY: Advancing the Science of Drug Discovery, 2017
    Co-Authors: Mohammad Reza Tohidkia, Jaleh Barar, Maryam Sepehri, Shirin Khajeh, Yadollah Omidi
    Abstract:

    Phage Display Technology (PDT) is a powerful tool for the isolation of recombinant antibody (Ab) fragments. Using PDT, target molecule-specific phage-Ab clones are enriched through the “biopanning” process. The individual specific binders are screened by the monoclonal scFv enzyme-linked immunosorbent assay (ELISA) that may associate with inevitable false-negative results. Thus, in this study, three strategies were investigated for optimization of the scFvs screening using Tomlinson I and J libraries, including (1) optimizing the expression of functional scFvs, (2) improving the sensitivity of ELISA, and (3) preparing different samples containing scFvs. The expression of all scFv Abs was significantly enhanced when scFv clones were cultivated in the terrific broth (TB) medium at the optimum temperature of 30 °C. The protein A–conjugated with horseradish peroxidase (HRP) was found to be a well-suited reagent for the detection of Ag-bound scFvs in comparison with either anti-c-myc Ab or the mixing procedure...

  • phage antibody Display libraries a powerful antibody discovery platform for immunotherapy
    Critical Reviews in Biotechnology, 2016
    Co-Authors: Aizhi Zhao, Mohammad Reza Tohidkia, Don L Siegel, George Coukos, Yadollah Omidi
    Abstract:

    AbstractPhage Display Technology (PDT), a combinatorial screening approach, provides a molecular diversity tool for creating libraries of peptides/proteins and discovery of new recombinant therapeu...

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Farzad Asadi, Mohammad Reza Tohidkia, Jaleh Barar, Yadollah Omidi
    Abstract:

    Background and Objective Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR.

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Mohammad Reza Tohidkia, Farzad Asadi, Jaleh Barar, Yadollah Omidi
    Abstract:

    Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR. To perform the SPB process, we utilized a synthetic biotinylated peptide corresponding to the second extracellular loop (ECL2) of CCK-BR and a semi-synthetic phage antibody library. After enzyme-linked immunosorbent assay (ELISA) screening, the CCK-BR specificity of the selected single-chain variable fragments (scFvs) were further examined using immunoblotting, whole-cell ELISA, and flow cytometry assays. After performing four rounds of selection, we identified nine antibody clones which showed positive reactivity with the CCK-BR peptide in an ELISA assay. Of these, eight clones were unique scFv antibodies and one was a VL single domain antibody. Specificity analysis of the selected scFvs revealed that five of the selected scFvs recognized a denatured form of CCK-BR, while the majority of the selected scFvs were able to recognize the native conformation of CCK-BR on the surface of human gastric adenocarcinoma cells and cervical carcinoma HeLa cells. For the first time, we report on the establishment of a diverse panel of scFv antibody fragments that are specific to the native conformation of CCK-BR. Based on these results, we suggest the selected scFv antibody fragments as potential agents for diagnosis, imaging, targeting, and/or immunotherapy of cancers that overexpress CCK-BR.

Mohammad Reza Tohidkia - One of the best experts on this subject based on the ideXlab platform.

  • improved soluble scfv elisa screening approach for antibody discovery using phage Display Technology
    SLAS DISCOVERY: Advancing the Science of Drug Discovery, 2017
    Co-Authors: Mohammad Reza Tohidkia, Jaleh Barar, Maryam Sepehri, Shirin Khajeh, Yadollah Omidi
    Abstract:

    Phage Display Technology (PDT) is a powerful tool for the isolation of recombinant antibody (Ab) fragments. Using PDT, target molecule-specific phage-Ab clones are enriched through the “biopanning” process. The individual specific binders are screened by the monoclonal scFv enzyme-linked immunosorbent assay (ELISA) that may associate with inevitable false-negative results. Thus, in this study, three strategies were investigated for optimization of the scFvs screening using Tomlinson I and J libraries, including (1) optimizing the expression of functional scFvs, (2) improving the sensitivity of ELISA, and (3) preparing different samples containing scFvs. The expression of all scFv Abs was significantly enhanced when scFv clones were cultivated in the terrific broth (TB) medium at the optimum temperature of 30 °C. The protein A–conjugated with horseradish peroxidase (HRP) was found to be a well-suited reagent for the detection of Ag-bound scFvs in comparison with either anti-c-myc Ab or the mixing procedure...

  • phage antibody Display libraries a powerful antibody discovery platform for immunotherapy
    Critical Reviews in Biotechnology, 2016
    Co-Authors: Aizhi Zhao, Mohammad Reza Tohidkia, Don L Siegel, George Coukos, Yadollah Omidi
    Abstract:

    AbstractPhage Display Technology (PDT), a combinatorial screening approach, provides a molecular diversity tool for creating libraries of peptides/proteins and discovery of new recombinant therapeu...

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Farzad Asadi, Mohammad Reza Tohidkia, Jaleh Barar, Yadollah Omidi
    Abstract:

    Background and Objective Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR.

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Mohammad Reza Tohidkia, Farzad Asadi, Jaleh Barar, Yadollah Omidi
    Abstract:

    Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR. To perform the SPB process, we utilized a synthetic biotinylated peptide corresponding to the second extracellular loop (ECL2) of CCK-BR and a semi-synthetic phage antibody library. After enzyme-linked immunosorbent assay (ELISA) screening, the CCK-BR specificity of the selected single-chain variable fragments (scFvs) were further examined using immunoblotting, whole-cell ELISA, and flow cytometry assays. After performing four rounds of selection, we identified nine antibody clones which showed positive reactivity with the CCK-BR peptide in an ELISA assay. Of these, eight clones were unique scFv antibodies and one was a VL single domain antibody. Specificity analysis of the selected scFvs revealed that five of the selected scFvs recognized a denatured form of CCK-BR, while the majority of the selected scFvs were able to recognize the native conformation of CCK-BR on the surface of human gastric adenocarcinoma cells and cervical carcinoma HeLa cells. For the first time, we report on the establishment of a diverse panel of scFv antibody fragments that are specific to the native conformation of CCK-BR. Based on these results, we suggest the selected scFv antibody fragments as potential agents for diagnosis, imaging, targeting, and/or immunotherapy of cancers that overexpress CCK-BR.

Jaleh Barar - One of the best experts on this subject based on the ideXlab platform.

  • improved soluble scfv elisa screening approach for antibody discovery using phage Display Technology
    SLAS DISCOVERY: Advancing the Science of Drug Discovery, 2017
    Co-Authors: Mohammad Reza Tohidkia, Jaleh Barar, Maryam Sepehri, Shirin Khajeh, Yadollah Omidi
    Abstract:

    Phage Display Technology (PDT) is a powerful tool for the isolation of recombinant antibody (Ab) fragments. Using PDT, target molecule-specific phage-Ab clones are enriched through the “biopanning” process. The individual specific binders are screened by the monoclonal scFv enzyme-linked immunosorbent assay (ELISA) that may associate with inevitable false-negative results. Thus, in this study, three strategies were investigated for optimization of the scFvs screening using Tomlinson I and J libraries, including (1) optimizing the expression of functional scFvs, (2) improving the sensitivity of ELISA, and (3) preparing different samples containing scFvs. The expression of all scFv Abs was significantly enhanced when scFv clones were cultivated in the terrific broth (TB) medium at the optimum temperature of 30 °C. The protein A–conjugated with horseradish peroxidase (HRP) was found to be a well-suited reagent for the detection of Ag-bound scFvs in comparison with either anti-c-myc Ab or the mixing procedure...

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Farzad Asadi, Mohammad Reza Tohidkia, Jaleh Barar, Yadollah Omidi
    Abstract:

    Background and Objective Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR.

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Mohammad Reza Tohidkia, Farzad Asadi, Jaleh Barar, Yadollah Omidi
    Abstract:

    Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR. To perform the SPB process, we utilized a synthetic biotinylated peptide corresponding to the second extracellular loop (ECL2) of CCK-BR and a semi-synthetic phage antibody library. After enzyme-linked immunosorbent assay (ELISA) screening, the CCK-BR specificity of the selected single-chain variable fragments (scFvs) were further examined using immunoblotting, whole-cell ELISA, and flow cytometry assays. After performing four rounds of selection, we identified nine antibody clones which showed positive reactivity with the CCK-BR peptide in an ELISA assay. Of these, eight clones were unique scFv antibodies and one was a VL single domain antibody. Specificity analysis of the selected scFvs revealed that five of the selected scFvs recognized a denatured form of CCK-BR, while the majority of the selected scFvs were able to recognize the native conformation of CCK-BR on the surface of human gastric adenocarcinoma cells and cervical carcinoma HeLa cells. For the first time, we report on the establishment of a diverse panel of scFv antibody fragments that are specific to the native conformation of CCK-BR. Based on these results, we suggest the selected scFv antibody fragments as potential agents for diagnosis, imaging, targeting, and/or immunotherapy of cancers that overexpress CCK-BR.

Farzad Asadi - One of the best experts on this subject based on the ideXlab platform.

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Farzad Asadi, Mohammad Reza Tohidkia, Jaleh Barar, Yadollah Omidi
    Abstract:

    Background and Objective Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR.

  • selection of potential therapeutic human single chain fv antibodies against cholecystokinin b gastrin receptor by phage Display Technology
    BioDrugs, 2013
    Co-Authors: Mohammad Reza Tohidkia, Farzad Asadi, Jaleh Barar, Yadollah Omidi
    Abstract:

    Gastric/gastrointestinal cancers are associated with high mortality worldwide. G-protein coupled receptor (GPCR) superfamily members such as gastrin/cholecystokinin-B receptor (CCK-BR) are involved in progression of gastric tumors, thus CCK-BR is considered as a potential target for immunotherapy. However, production of functional monoclonal antibodies (mAbs) against GPCR seems to be very challenging, in part due to its integration in cell membranes and inaccessibility for selection. To tackle this problem, we implemented phage Display Technology and a solution-phase biopanning (SPB) scheme for production of mAbs specific to the native conformation of CCK-BR. To perform the SPB process, we utilized a synthetic biotinylated peptide corresponding to the second extracellular loop (ECL2) of CCK-BR and a semi-synthetic phage antibody library. After enzyme-linked immunosorbent assay (ELISA) screening, the CCK-BR specificity of the selected single-chain variable fragments (scFvs) were further examined using immunoblotting, whole-cell ELISA, and flow cytometry assays. After performing four rounds of selection, we identified nine antibody clones which showed positive reactivity with the CCK-BR peptide in an ELISA assay. Of these, eight clones were unique scFv antibodies and one was a VL single domain antibody. Specificity analysis of the selected scFvs revealed that five of the selected scFvs recognized a denatured form of CCK-BR, while the majority of the selected scFvs were able to recognize the native conformation of CCK-BR on the surface of human gastric adenocarcinoma cells and cervical carcinoma HeLa cells. For the first time, we report on the establishment of a diverse panel of scFv antibody fragments that are specific to the native conformation of CCK-BR. Based on these results, we suggest the selected scFv antibody fragments as potential agents for diagnosis, imaging, targeting, and/or immunotherapy of cancers that overexpress CCK-BR.

Jennifer Blain Christen - One of the best experts on this subject based on the ideXlab platform.

  • application of flat panel oled Display Technology for the point of care detection of circulating cancer biomarkers
    Scientific Reports, 2016
    Co-Authors: Benjamin A. Katchman, Joseph T. Smith, Jennifer Blain Christen, Barry Obrien, Uwadiae Obahiagbon, Sailaja Kesiraju, Korhan Kaftanoglu, Karen S. Anderson
    Abstract:

    Point-of-care molecular diagnostics can provide efficient and cost-effective medical care and they have the potential to fundamentally change our approach to global health. However, most existing approaches are not scalable to include multiple biomarkers. As a solution, we have combined commercial flat panel OLED Display Technology with protein microarray Technology to enable high-density fluorescent, programmable, multiplexed biorecognition in a compact and disposable configuration with clinical-level sensitivity. Our approach leverages advances in commercial Display Technology to reduce pre-functionalized biosensor substrate costs to pennies per cm2. Here, we demonstrate quantitative detection of IgG antibodies to multiple viral antigens in patient serum samples with detection limits for human IgG in the 10 pg/mL range. We also demonstrate multiplexed detection of antibodies to the HPV16 proteins E2, E6 and E7, which are circulating biomarkers for cervical as well as head and neck cancers.

  • Application of Flexible OLED Display Technology to Point-of-Care Medical Diagnostic Testing
    Journal of Display Technology, 2016
    Co-Authors: Joseph T. Smith, Yong Kyun Lee, Benjamin A. Katchman, Dixie E. Kullman, Uwadiae Obahiagbon, Barry P. O'brien, Gregory B. Raupp, Karen S. Anderson, Jennifer Blain Christen
    Abstract:

    This paper presents a new concept combining flexible organic light-emitting diode (OLED) Display Technology with fluorescent biorecognition microarray Technology to fabricate point-of-care immunobiosensors. Our approach is designed to leverage commercial OLED Display Technology to reduce pre-functionalized biosensor substrate costs to pennies per cm2 combined with leveraging the Display industries ability to manufacture an immense number of low-cost consumer electronic products annually. For this work, we demonstrate that our new approach using high brightness flexible OLED Display Technology combined with a charge integrating readout circuit and optical filters can offer point-of-care diagnostic sensitivity at or below 10 pg/mL, which approaches the lower limit of detection (LLOD) of typical clinical laboratory instrumentation.

  • application of flexible oled Display Technology for electro optical stimulation and or silencing of neural activity
    IEEE\ OSA Journal of Display Technology, 2014
    Co-Authors: Joseph T. Smith, Edward J. Bawolek, Yong Kyun Lee, Barry Obrien, Jennifer Blain Christen
    Abstract:

    This paper presents a new biophotonic application for large-area, high-resolution, flexible organic light-emitting diode (OLED) Display Technology currently used to manufacture low-cost color flexible Displays on plastic substrates. The new concept uses a fully addressable high resolution flexible OLED pixel array on a thin, mechanically compliant biocompatible plastic substrate to selectively stimulate and/or silence small groups of neurons on either the cortical surface or, alternatively, within the deep brain. Optical measurements from a 455 nm blue flexible OLED test structure demonstrated the ability to emit 1 ${\hbox{mW/mm}}^{2}$ of instantaneous light intensity using a 13 V, 20 Hz pulse, which meets the minimum reported intensity at $\sim$ 450 nm to induce optical stimulation in genetically modified neural tissue. Biocompatibility was successfully demonstrated by the ability to grow human epithelial cells on the surface of a full TFT process flow plastic flexible Display substrate. Additionally, a new active matrix array Display architecture was designed to support pulsed mode OLED operation. These preliminary results demonstrate the initial viability of extending flexible plastic substrate OLED Display Technology to the development of large-area, high-resolution emissive active matrix arrays for chronic optogenetic applications.